NEW FILINGS<\/strong><\/p>\nCompany: PhaseBio Pharmaceuticals
\nSymbol: PHAS
\nDescription: They are a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Citigroup, Cowen, Stifel
\nFiled: 9-21-18
\nListed Cash Raise: $86.25m<\/p>\n
Company: Solarwinds Corporation
\nSymbol: SWI
\nDescription: SolarWinds is a leading provider of information technology, or IT, infrastructure management software.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Goldman Sachs, JP Morgan, , Credit Suisse, BofA Merrill Lynch, Barclays, Citigroup, Evercore, Jefferies, Macquarie Capital, Nomura, RBC Capital
\nCo-Manager(s): Baird, JMP Securities, KeyBanc Capital, SunTrust Robinson
\nFiled: 9-21-18
\nListed: Cash Raise: $500m<\/p>\n
Company: Niu Technologies
\nSymbol: NIU
\nDescription: They are the world’s leading provider of smart urban mobility solutions, according to CIC.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Credit Suisse, Citigroup
\nCo-Manager(s): Needham
\nFiled: 9-24-18
\nListed: Cash Raise: $150m<\/p>\n
Company: Valtech SE
\nSymbol: VTEC
\nDescription: Valtech is a next-generation business transformation services provider focused on helping medium and large organizations as they embrace the digital age.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): J.P. Morgan, Morgan Stanley
\nCo-Manager(s): Cowen, Oddo BHF, William Blair\u200b
\nFiled: 9-25-18
\nListed: Cash Raise: $100m<\/p>\n
Company: LogicBio Therapeutics, Inc.
\nSymbol: LOGC
\nDescription: They are a genome editing company focused on developing medicines to durably treat rare diseases in patients with significant unmet medical need using GeneRide, our proprietary technology platform.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Jefferies, Barclays, William Blair, Chardan\u200b
\nFiled: 9-25-18
\nListed: Cash Raise: $86.25m<\/p>\n
Company: YETI Holdings
\nSymbol: YETI
\nDescription: They are a rapidly growing designer, marketer, and distributor of premium products for the outdoor and recreation market.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): BofA Merrill Lynch, Morgan Stanley, Jefferies
\nCo-Manager(s): Baird, Piper Jaffray, Citigroup, Goldman Sachs, KeyBanc, William Blair, Raymond James, Stifel
\nFiled: 9-28-18
\nListed Cash Raise: $100m
\nNote: First filed in July 2016<\/p>\n
Company: Revolve Group, Inc.
\nSymbol: RVLV
\nDescription: REVOLVE is the next-generation fashion retailer for millennial consumers.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, Credit Suisse, BofA Merrill Lynch
\nCo-Manager(s): Barclays, Jefferies, Cowen, Guggenheim Securities, Raymond James, William Blair
\nFiled: 9-28-18
\nListed Cash Raise: $100m<\/p>\n
Company: Samoyed Holding Limited
\nSymbol: SMY
\nDescription: They are the only loan facilitator in China focused on facilitating credit card balance transfer products with a weighted average APR lower than 18.25%, the annual interest rate cap for credit cards set by the PRC regulators, according to Oliver Wyman.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Morgan Stanley, Deutsche Bank, CICC
\nFiled: 9-28-18
\nListed Cash Raise: $80m<\/p>\n
Company: Arog Pharmaceuticals, Inc.
\nSymbol: AROG
\nDescription: They are a late-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing crenolanib in indications with high unmet need.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Citigroup, RBC Capital, Nomura
\nFiled: 9-28-18
\nListed Cash Raise: $74.75m<\/p>\n
Company: NGM Biopharmaceuticals, Inc.
\nSymbol: NGM
\nDescription: They are a clinical-stage biopharmaceutical company developing novel therapeutics based on our scientific understanding of key biological pathways underlying cardio-metabolic, liver, oncologic and ophthalmic diseases.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): Goldman Sachs, Citigroup, Cowen
\nFiled: 9-28-18
\nListed Cash Raise: $75m<\/p>\n
Company: Gamida Cell Ltd.
\nSymbol: GMDA
\nDescription: They are a clinical stage biopharmaceutical company leveraging our proprietary technology to develop cell therapies that are designed to cure cancer and rare, serious hematologic diseases.
\nTrade Date: TBD
\nShares: TBD
\nPrice Range: TBD
\nUnderwriter(s): BMO Capital, RBC Capital
\nCo-Manager(s): Needham & Co., Oppenheimer & Co.
\nFiled: 9-28-18
\nListed Cash Raise: $69m<\/p>\n
TERMS ADDED<\/p>\n
Company: Upwork Inc.
\nSymbol: UPWK
\nDescription: They operate the largest online global marketplace that enables businesses to find and work with highly-skilled freelancers as measured by gross services volume, or GSV.
\nTrade Date: 10\/3
\nShares: 12.3 million
\nPrice Range: $10.00-$12.00
\nUnderwriter(s): Citigroup, Jefferies, RBC, Stifel, JMP Securities
\nTerms Added: 9-21-18<\/p>\n
Company: Guardant Health
\nSymbol: GH
\nDescription: They are a leading precision oncology company focused on helping conquer cancer globally through use of their proprietary blood tests, vast data sets and advanced analytics.
\nTrade Date: 10\/4
\nShares: 12.5 million
\nPrice Range: $15.00-$17.00
\nUnderwriter(s): JP Morgan, BofA Merrill Lynch
\nCo-Manager(s): Cowen, Leerink Partners, William Blair
\nTerms Added: 9-21-18<\/p>\n
Company: Kodiak Sciences Inc.
\nSymbol: KOD
\nDescription: They are a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases.
\nTrade Date: 10\/4
\nShares: 9 million
\nPrice Range: $13.00-$15.00
\nUnderwriter(s): Morgan Stanley, BofA Merrill Lynch
\nCo-Manager(s): Barclays, Chardan
\nTerms Added: 9-24-18<\/p>\n
Company: Elastic N.V.
\nSymbol: ESTC
\nDescription: Elastic is a search company. Search is foundational to a wide variety of experiences. Elastic makes the power of search\u2014the ability to instantly find relevant information and insights from large amounts of data\u2014available for a diverse set of applications and use cases.
\nTrade Date: 10\/5
\nShares: 7 million
\nPrice Range: $26.00-$29.00
\nUnderwriter(s): Goldman Sachs & Co., J.P. Morgan, Barclays, RBC Capital Markets
\nCo-Manager(s): BofA Merrill Lynch, Citigroup, Jefferies, Canaccord Genuity
\nTerms Added: 9-24-18<\/p>\n","protected":false},"excerpt":{"rendered":"
This is the latest look at the IPO Pipeline including the newest filings that have registered with the SEC in the last seven days.<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"zakra_general_container_width":0,"zakra_general_content_width":0,"zakra_general_sidebar_width":0,"zakra_sticky_header":"customizer","zakra_header_main_area":true,"zakra_site_logo_width":0,"zakra_header_top_enabled":"customizer","zakra_header_top_style":"customizer","zakra_primary_menu_item_style":"customizer","zakra_page_header_text_color":"","zakra_page_header_layout":"customizer","zakra_page_title_bg":"","zakra_footer_widgets_bg_image":0,"zakra_page_title_bg_repeat":"customizer","zakra_page_title_bg_position":"customizer","zakra_page_title_bg_size":"customizer","zakra_page_title_bg_attachment":"customizer","zakra_breadcrumbs_enabled":"customizer","zakra_breadcrumbs_text_color":"","zakra_breadcrumbs_separator_color":"","zakra_breadcrumbs_link_color":"","zakra_breadcrumbs_link_hover_color":"","zakra_page_title_bg_image":0,"zakra_footer_widgets_enabled":"customizer","zakra_footer_column_layout_1_style":"customizer","zakra_footer_widgets_bg":"","zakra_footer_widgets_bg_repeat":"customizer","zakra_footer_widgets_bg_position":"customizer","zakra_footer_widgets_bg_size":"customizer","zakra_footer_widgets_bg_attachment":"customizer","zakra_footer_bar_enabled":"customizer","zakra_footer_bar_style":"customizer","footnotes":""},"categories":[24,1536],"tags":[],"class_list":["post-5395","post","type-post","status-publish","format-standard","hentry","category-ipo","category-subscriber-content"],"_links":{"self":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5395","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/comments?post=5395"}],"version-history":[{"count":5,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5395\/revisions"}],"predecessor-version":[{"id":5423,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/posts\/5395\/revisions\/5423"}],"wp:attachment":[{"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/media?parent=5395"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/categories?post=5395"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipoboutique.com\/blog\/wp-json\/wp\/v2\/tags?post=5395"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
![\"\"](\"http:\/\/www.ipoboutique.com\/blog\/wp-content\/uploads\/2018\/09\/Screen-Shot-2018-09-28-at-9.14.43-AM-300x101.png\")
<\/a><\/p>\n